Drugs / BCMA-PD1-CART Cell
BCMA-PD1-CART Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04162119 | Jul 2019 → Oct 2021 | plasma cell myeloma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-PD1-CART Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162119 ↗ |
| Known as | BCMA CART cells | “The investigators prepared BCMA CART cells which secretes the mutant PD-1Fc fusion protein” NCT04162119 ↗ |
| Known as | BCMA-PD1-CART cells | “BCMA-PD1-CART cells therapy” NCT04162119 ↗ |
| Action | Deplete | “have a superior killing effect on PD-L1 positive multiple myeloma tumor cells” NCT04162119 ↗ |
| Modality | Cell therapy | “BCMA-PD1-CART cells therapy” NCT04162119 ↗ |